GTC
RARE icon

Ghost Tree Capital’s Ultragenyx Pharmaceutical RARE Stock Holding History

Ghost Tree Capital’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-20,000
Closed -$934K – 81
2024
Q1 		$934K Buy
+20,000
New +$943K 0.26% 69

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Ghost Tree Capital's RARE Position: Q2 2024 in Review

Ghost Tree Capital sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2024, closing a stake of 20,000 shares — an estimated $934K sold.

Ghost Tree Capital first reported a position in RARE in Q1 2024 and held it in 1 quarter. The position peaked at $934K in Q1 2024. 274 funds tracked by Wall St. Rank hold RARE as of Q2 2024.

  • Ghost Tree Capital reported no remaining Ultragenyx Pharmaceutical position as of Q2 2024 after selling out during the quarter.
  • Ghost Tree Capital sold 20,000 Ultragenyx Pharmaceutical shares in Q2 2024, an estimated $934K.
  • Ghost Tree Capital first reported a position in Ultragenyx Pharmaceutical in Q1 2024 and held it in 1 quarter.
  • Ghost Tree Capital's Ultragenyx Pharmaceutical position peaked at $934K in Q1 2024.
  • 274 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2024.

Based on Ghost Tree Capital's 13F filing for Q2 2024, filed 14 Aug 2024.